Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)

Phase 1 Unknown 15 enrolled The Second Affiliated Hospital of Fujian Medical University Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China · collab

NaSingle-groupOpen-labelTreatment

Summary

HTLV-1 Associated Myelopathy is a chronic disease of the spinal cord, caused by a virus called human T lymphotropic virus type 1（HTLV-1）. Natural Killer cells provide rapid responses to viral-infected cells, acting at around 3 days after infection, and respond to tumor formation. In this trial, the investigators aim to study the therapeutic safety and the effect on HTLV-1 virus. This in turn will improve the knowledge and understanding of the disease and should lead to better therapy.

Timeline

Start: 2016-07
Primary completion: 2017-10
Completion: 2017-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TROCULEUCEL	Cell therapy	9e+08 cells	Intravenous
Subject	TROCULEUCEL	Cell therapy	1e+09 cells	Intravenous
Background	amniotic epithelial cells	Cell therapy	—	Intrathecal

Indications

No indication recorded.